LYEL vs. CRMD, IMNM, ABUS, BCYC, DNTH, KURA, CDXC, KALV, MGTX, and VALN
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include CorMedix (CRMD), Immunome (IMNM), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), MeiraGTx (MGTX), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs.
Lyell Immunopharma (NASDAQ:LYEL) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Lyell Immunopharma has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
In the previous week, CorMedix had 25 more articles in the media than Lyell Immunopharma. MarketBeat recorded 34 mentions for CorMedix and 9 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.51 beat CorMedix's score of 0.55 indicating that Lyell Immunopharma is being referred to more favorably in the media.
CorMedix has higher revenue and earnings than Lyell Immunopharma. CorMedix is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
CorMedix has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat CorMedix's return on equity.
Lyell Immunopharma presently has a consensus price target of $1.00, suggesting a potential upside of 90.11%. CorMedix has a consensus price target of $15.14, suggesting a potential upside of 142.05%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Lyell Immunopharma.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by company insiders. Comparatively, 5.2% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CorMedix received 17 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 79.49% of users gave CorMedix an outperform vote while only 46.67% of users gave Lyell Immunopharma an outperform vote.
Summary
CorMedix beats Lyell Immunopharma on 12 of the 19 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 3/31/2025 by MarketBeat.com Staff
Buy LYEL Stock Free LYEL Stock Alerts